Concepedia

Author

Suso Platero

Janssen (United States)

Also Known As

S Platero, S. Platero, Suso J. Platero, Suso Platero

83

Publications

1.8K

Citations

13

H-Index

18

Concepts

All Affiliations

Janssen (United States)Roswell Park Comprehensive Cancer CenterInstitut Gustave RoussyJohnson & Johnson (United States)Janssen (Belgium)
SP

About

Suso Platero is an author at Janssen (United States) specializing in pathology, cell biology, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

165

2

Cell Biology

3

3

165

3

Pathology

3

3

165

4

Pharmacology

2

2

65

5

Cancer Cell Biology

1

1

43

Suso Platero

×

12

Publications

1.7K

Citations

12

H-Index

YearCitations

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann,

Journal of Clinical Oncology

2015

371

Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection

Fei Huang, Karen A. Reeves, Xia Han,

Cancer Research

2007

337

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Timothy Perera, Eleonora Jovcheva, Laurence Mévellec,

Molecular Cancer Therapeutics

2017

335

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients

Xu‐Chao Zhang, Jun Wang, Guoguang Shao,

Nature Communications

2019

225

The Case for a Pre-Cancer Genome Atlas (PCGA)

Joshua D. Campbell, Sarah A. Mazzilli, Mary E. Reid,

Cancer Prevention Research

2016

100

Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions

Jennifer Beane, Sarah A. Mazzilli, Joshua D. Campbell,

Nature Communications

2019

96

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

Josep Tabernero, Luc Dirix, Patrick Schöffski,

Clinical Cancer Research

2011

62

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

Jayaprakash D. Karkera, Gabriela Martinez Cardona, Katherine Bell,

Molecular Cancer Therapeutics

2017

62

Detecting the Presence and Progression of Premalignant Lung Lesions via Airway Gene Expression

Jennifer Beane, Sarah A. Mazzilli, Anna M. Tassinari,

Clinical Cancer Research

2017

48

Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.

Rastislav Bahleda, Rodrigo Dienstmann, Bárbara Adamo,

Journal of Clinical Oncology

2014

43

Page 1